Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Making cancer cells susceptible to therapeutic attack

23.08.2002


A researcher at the University of Illinois at Chicago College of Medicine is discovering how a gene known as E1A, found in a virus responsible for the common cold, renders tumor cells vulnerable to destruction.



"By explaining how E1A works, we hope to develop novel strategies to make human immunological defenses against tumors, as well as chemotherapy and radiation therapy, more effective in combating cancer," said Dr. James Cook, chief of infectious diseases and a member of the UIC Cancer Center.

The latest study is published in the July 23 issue of the Proceedings of the National Academy of Sciences.


To date, Cook and his colleagues have tested the E1A gene in cancer cells from four species: hamsters, mice, rats and humans. In all four cases, E1A renders the malignancies susceptible to defender cells of the immune system.

"We believe that these observations may reveal a common Achilles heel of many types of cancer cells," Cook said.

According to Cook, the goal is to find ways to make standard treatments for cancer more effective. Although the disease may respond to the first course of chemotherapy or radiation, typically tumor cells become more resistant later on, when the cancer recurs or metastasizes. The reasons are not clear.

Possibly, series of mutations are acquired as the tumor grows, yielding a naturally selected population of cells capable of thwarting killing agents. The standard clinical course is to change the drug or radiation strategy, but that may not be feasible or useful.

As an alternative, based on the studies Cook is undertaking, physicians may one day be able to alter the resistant malignant tissue itself, making it vulnerable to therapy.

"E1A is helping us identify the set of cellular switches that need to be turned on or off to render cancer cells more sensitive to therapeutic injury," Cook said.

In the present study, Cook and his colleagues examined a chain of molecular events that occur when cancer cells are confronted with one of the battery of chemicals produced by the immune system. The laboratory experiment mimicked what happens when a tumor begins to grow and the immune system tries to destroy the malignancy.

The chemical used in the study, called tumor necrosis factor, is manufactured primarily by macrophages, which are among the first cells on the scene in an immune response to tumors. When tumor necrosis factor attaches to receptors on the surface of a malignant cell, preparing the way for a full-scale attack, the cancer cell typically blocks the assault.

But when the E1A gene is inserted in the malignant cells, it shuts down the tumor’s defense mechanism. Cook showed that one key step in foiling the defense occurs when E1A gene products bind to cellular retinoblastoma proteins -- proteins that normally regulate a cell’s life cycle.

The finding suggests that the E1A gene renders malignant cells susceptible to attack not by interfering with their physiological functioning, but by preventing their use of normal cellular machinery to avoid destruction by the body’s immune defenses.

"Multiple molecular mechanisms triggered by E1A prevent tumor cells from thwarting an immunological attack," Cook said. "Further definition of these mechanisms will help us develop new concepts that may be useful for treating cancer, in part by enlisting the body to become a more active partner in fighting the disease."

Sharon Butler | EurekAlert!
Further information:
http://www.uic.edu/
http://www.uic.edu/com/cancer

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>